PT - JOURNAL ARTICLE AU - Eric Lu AU - Aki Hara AU - Shudong Sun AU - Brian Hallmark AU - Justin M. Snider AU - Michael C. Seeds AU - Joseph C. Watkins AU - Charles E. McCall AU - Hao Helen Zhang AU - Guang Yao AU - Floyd H. Chilton TI - Temporal Associations of Plasma Levels of the Secreted Phospholipase A<sub>2</sub> Family and Mortality in Severe COVID-19 AID - 10.1101/2022.11.21.22282595 DP - 2022 Jan 01 TA - medRxiv PG - 2022.11.21.22282595 4099 - http://medrxiv.org/content/early/2022/11/22/2022.11.21.22282595.short 4100 - http://medrxiv.org/content/early/2022/11/22/2022.11.21.22282595.full AB - Previous research suggests that group IIA secreted phospholipase A2(sPLA2-IIA) plays a role in and predicts severe COVID-19 disease. The current study reanalyzed a longitudinal proteomic data set to determine the temporal (days 0, 3 and 7) relationship between the levels of several members of a family of sPLA2 isoforms and the severity of COVID-19 in 214 ICU patients. The levels of six secreted PLA2 isoforms, sPLA2-IIA, sPLA2-V, sPLA2-X, sPLA2-IB, sPLA2-IIC, and sPLA2-XVI, increased over the first 7 ICU days in those who succumbed to the disease. sPLA2-IIA outperformed top ranked cytokines and chemokines as predictors of patient outcome. A decision tree corroborated these results with day 0 to day 3 kinetic changes of sPLA2-IIA that separated the death and severe categories from the mild category and increases from day 3 to day 7 significantly enriched the lethal category. In contrast, there was a time-dependent decrease in sPLA2-IID and sPLA2-XIIB in patients with severe or lethal disease, and these two isoforms were at higher levels in mild patients. Taken together, proteomic analysis revealed temporal sPLA2 patterns that reflect the critical roles of sPLA2 isoforms in severe COVID-19 disease.Competing Interest StatementDr. Chilton is a cofounder of Tyrian Omega, Inc, and Resonance Pharma, Inc. These companies use microorganisms to generate omaga-3 fatty acids and develop diagnostic and therapeutics for lipid targets, respectively. These commercial relationships are managed by the Office for Responsible Outside Interests at University of Arizona.Funding StatementThis study was supported by NCCIH R01 AT008621 and USDA ARZT-1361680-H23-157.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The datasets analyzed for this study were openly available before initiation of this study. Datasets can be found at Data Mendeley: https://data.mendeley.com/datasets/nf853r8xsj/2, accession number: DOI:10.17632/nf853r8xsj.2.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at Data Mendeley. https://data.mendeley.com/datasets/nf853r8xsj/2